Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
The University of Texas MD Anderson Cancer Center · Cancer Institute (WIA) · +43 more institutions
Abstract
Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing, especially analysis of HER2 status, microsatellite instability (MSI) status, and the expression of programmed death-ligand 1 (PD-L1), has had a significant impact on clinical practice and patient care. Targeted therapies…
Citation impact
- FWCI
- 236.46
- Percentile
- 100%
- References
- 174
Authors
41- JAJaffer A. AjaniCorresponding
The University of Texas MD Anderson Cancer Center
- TAThomas A. D’Amico
Cancer Institute (WIA), Duke Cancer Institute
- DJDavid J. Bentrem
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- JCJoseph Chao
City Of Hope National Medical Center
- DTDavid T. Cooke
UC Davis Comprehensive Cancer Center, University of California, Davis
Topics & keywords
- Medicine
- Nivolumab
- Cancer
- Pembrolizumab
- Oncology
- Internal medicine
- Microsatellite instability
- Palliative care
- Good health and well-being